vermillion inc (VRML:NASDAQ CM)

Executive Profile*

Background*

Dr. Daniel W. Chan PhD, DABCC, FACB is Professor of Pathology, Oncology, Urology and Radiology, Director of Clinical Chemistry Division, Department of Pathology, and the Director, Center for Biomarker Discovery at the Johns Hopkins University School of Medicine. Dr. Chan serves as the Co-Principal Investigator of JHU Prostate Cancer. Responsibilities including the heading of hospital clinical chemistry laboratory, he conducts cutting edge research using state of the ... art proteomic techniques for biomarker discovery. He serves as the Editor-in-Chief of the journal Clinical Proteomics. He is particularly well-known as a Leader in the concept and methodology of the clinical usefulness of prostate-specific antigen (PSA) as a Marker for prostate cancer. His research has led to major findings showing the importance of analytical methodologies of laboratory testing in diagnosing, managing and understanding human cancers. Dr. Chan has been a Member of Scientific Advisory Board at Courtagen Life Sciences, Inc (also known as Decision Biomarkers, Inc.) since December 2008 and Vermillion, Inc. (formerly, Ciphergen Biosystems, Inc.) since June 2006. He serves as a Member of Scientific Advisory Board of Onconome, Inc. He served as a Member of the General Strategic Advisory Board of DiagnoCure Inc. Dr. Chan has authored or co-authored over 120 articles on subjects including tumor markers, endocrinology and immunoassay, as well as the chapter on tumor markers in the Tietz Textbook of Clinical Chemistry. He has published over 200 scientific articles, five books on immunoassay automation, endocrinology, and tumor markers. He is an internationally recognized authority in clinical chemistry, proteomics, immunoassay, and biochemical tumor markers (particularly breast and prostate cancer markers). Dr. Chan received his Ph.D. from the State University of New York at Buffalo.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
VRML:US	$2.78 USD	+0.01

COMPETITOR COMPENSATION